Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2004; 25(01): 28-31
DOI: 10.1055/s-0041-1733061
Original Article

Second Look Laparotomy for Ovarian Cancer: Past, Present and Future

S.V.S DEO
Department of Surgical Oncology, IRCH-AIIMS, New Delhi, India
,
ATUL SAMAIYA
Department of Surgical Oncology, IRCH-AIIMS, New Delhi, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
28 March 2022

© 2004. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rutledge F, Burns B. Chemotherapy for advanced ova¬rian cancer. Am J Obstet Gynecol. 1966 ; 96(6):761-72.
  • 2 lund B. Jacobsen K, Rasch L, Jensen F, Olesen K, Feldt-Rasmussen K. Correlation of abdominal ultra¬sound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma. Gynecol Oncol, 1990; 37(2):279-83.
  • 3 Rubin SC, Hoskins WJ, Hakes TB, Markman M, Cain JM, Lewis JL Jr. Recurrence after negative second- look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol. 1988; 159(5):1094-8.
  • 4 Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC Jr CA 125 serum lev¬els correlated with second-look operations among ovarian cancer patients. Obstet Gynecol. 1986; 67(5):685-9.
  • 5 Senapad S, Neungton S, Thirapakawong C, Suphanit I, Hangsubcharoen M, Thamintorn K. Predictive value of the combined se¬rum CA 125 and TPS during chemotherapy and be¬fore second-look laparotomy in epithelial ovarian cancer. Anticancer Res. 2000; 20(2B):1297-300.
  • 6 McGowan L, Bunnag B. The evaluation of therapy for ovarian cancer Gynecol Oncol. 1976; 4(4):375-83.
  • 7 Ozols RF, Fisher RI, Anderson T, Makuch R, Young RC. Peritoneoscopy in the management of ovarian cancer. Am J Obstet Gynecol. 198; 140(6):6U-9.
  • 8 Husain A, Chi DS, Prasad M, Abu-Rustum N, Barakat RR, Brown CL, et al The role of laparoscopy in sec¬ond-look evaluations for ovarian cancer. . Gynecol Oncol. 2001 Jan;80 (l):44-7
  • 9 Rose PG, Faulhaber R Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a com¬plete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 2001 Jul; 82(1): 17-21.
  • 10 10. Hubner KF, McDonald TW, Niethammer JG, Smith GT, Could HRBuonocore E. Assessment of primary and metastatic Ovarian cancer by positive emission to-mography (PET) using 2-["'F]deoxyglucose (2-[wF]FDG). Gynecol Oncol 1993; 51:197-204.
  • 11 Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithe¬lial Ovarian cancer. Principle and Practice of Gyne¬cologic Oncology 3nl Edtion. Lippincott Williams and Wilkins. New York, 2000; 981-1057.
  • 12 Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow up of ovarian cancer patients af¬ter second look laparotomy with negative findings. Obst Gynecol 1999; 93:21-4.
  • 13 Williums L, Brunetto VL, Yordan E, DiSaia PJ, Creasman WT. Secondary cytoreductive surgery at sec¬ond look laparotomy in advanced ovarian cancer: A Gynecologic Oncology group study. Gynecol Oncol 1997; 66: 171-8.
  • 14 Fiedman RL, Eisenkop SM, Wang HJ. Second look lap¬arotomy for ovarian cancer provides reliable prognos¬tic information and improve survival. Gynecol Oncol 1997; 67: 88-94.
  • 15 Tuxen MK, Strauss G, Lund B, Hansen M. The role of second look laparotomy in the long-term survival in ovarian cancer. Ann Oncol 1997; 8: 643-8.
  • 16 Hempling RE, Wesolowski JA, Piver MS. Second look laparotomy in advanced ovarian cancer: Critical as¬sessment of morbidity and impact on survival. Ann Surg Oncol 1997; 4: 349-54.
  • 17 Millar DS, Spirtos N, Ballon SC, Cox RS, Soriero OM, Teng NN. Critical assessment of second look laparo¬tomy in epithelial ovarian carcinoma. Cancer 1992; 69: 502-10.
  • 18 Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin (CIS)/paclilaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithe¬lial ovarian cancer (OC): a Gynecologic Oncology group Trial (GOG 1589). Proc Am Soc Clin Oncol 1999; 18: 356a (abstract).
  • 19 Rubin SC, Sutton GP, eds. Second-look Laparotomy. Ovarian cancer. New York: McGraw-Hill, 1993:269-300.
  • 20 Rubin SC, Hoskins WJ, Hakes TB, Markman M, Reichman BS, Chapman D, Lewis JL Jr. Serum CA 125 levels and surgical findings in patients undergoing sec¬ondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 1989 160(3):667-71.